Abstract:Abstract Background: Tumors often demonstrate initial responses to cisplatin-based chemotherapy in treating non-small cell lung cancer (NSCLC), but eventually develop resistance and limit the success of therapy. We investigated whether IL-6 signaling is important in developing cisplatin-resistance of NSCLC and explore if targeting IL-6 signaling may increase tumor sensitivity to cisplatin. Methods: We performed in vitro cytotoxicity test using the IL-6 knocked down and scramble (sc) control A549 and H157 NSCLC cell lines (A549IL-6si/sc and H157IL-6si/sc). We also performed in vivo mice studies by establishing xenografts using the A549IL-6si/sc cell set. We next examined the mechanism by which IL-6 mediates cisplatin resistance by performing studies of qPCR, Western analyses, and applying inhibitors of intracellular signaling molecules. Finally, we independently developed the cisplatin resistant A549 (A549CisR) and H157(H157CisR) cell lines and investigated whether targeting IL-6 signaling using a neutralizing antibody of IL-6 could prime these cicplatin-resistant cells to increase the sensitivity to cisplatin. Results: The in vitro survival tests revealed that cisplatin was more cytotoxic to the IL-6 knocked down A549IL-6si and H157IL-6si cells than sc control cells. In in vivo mice studies, we consistently observed more effective tumor regression in A549IL-6si cells-derived xenografts than sc cells-derived tumors (control) after cisplatin treatments. In mechanistic studies, we found that expressions of the anti-apoptotic proteins (Bcl-2 and Mcl-1) and the molecules associated with DNA repair (ATM, CHK1, TP73, p53, and ERCC1) were significantly increased upon cisplatin treatment in A549sc and H157sc cells, but not in IL-6si cells of A549 and H157. The molecular inhibitor studies further revealed that the activation of signaling pathways, such as Stat3, Akt, MAPK, and Erk, was responsible for the up-regulation of these molecules. Further, when we treated cisplatin resistant-A549 and H157 cell lines (A549CisR and H157CisR) with a neutralizing antibody of IL-6, we observed increased cell cytotoxicity. Conclusions and Impact: Our data support that the IL-6 signaling may be critical in conferring NSCLC cell resistance to cisplatin. In addition, we demonstrated that targeting IL-6 signaling could overcome the established acquired cisplatin resistance. Our observation supports a possible strategy to overcome cisplatin resistance through targeting IL-6 signaling or its downstream molecule(s) in treating NSCLC. Citation Format: Shan-zhou Duan, Ying Tsai, Peter Keng, Yongbing Chen, Soo Ok Lee, Yuhchyau Chen. IL-6 signaling modulates cisplatin resistance in non-small cell lung cancer via up-regulations of anti-apoptotic and DNA repair associated molecules. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 740. doi:10.1158/1538-7445.AM2015-740

IL-7-Mediated IL-7R-JAK3/STAT5 signalling pathway contributes to chemotherapeutic sensitivity in non-small-cell lung cancer.

Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2

IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Abstract 740: IL-6 Signaling Modulates Cisplatin Resistance in Non-Small Cell Lung Cancer Via Up-Regulations of Anti-Apoptotic and DNA Repair Associated Molecules

CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells.

CXCL12 Suppresses Cisplatin-Induced Apoptosis Through Activation of JAK2/STAT3 Signaling in Human Non-Small-cell Lung Cancer Cells

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

IL ‐8 from CD248 ‐expressing cancer‐associated fibroblasts generates cisplatin resistance in non‐small cell lung cancer

ZNF300 promotes chemoresistance and aggressive behaviour in non‐small‐cell lung cancer

5-Fluorouracil and Interleukin-2 Immunochemotherapy Enhances Immunogenicity of Non-Small Cell Lung Cancer A549 Cells Through Upregulation of NKG2D Ligands.

Prognostic Significance of STAT3 Expression and Its Correlation with Chemoresistance of Non-Small Cell Lung Cancer Cells

Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin

The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells

Wnt5a Increases Properties of Lung Cancer Stem Cells and Resistance to Cisplatin through Activation of Wnt5a/PKC Signaling Pathway

[Interleukin 7 and Its Receptor Promote Cell Proliferation and Induce Lymphangiogenesis in Non-Small Cell Lung Cancer].

Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2

Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer